Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers November 19, 2017
Pharmacy Choice - News - Pharmaceutical Development - November 19, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

12/31/16 - ABIVAX reports on ABX464 as HIV functional cure and treatment for inflammatory diseases
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Paris, 8 December 2016- ABIVAX, an innovative biotechnology company targeting the immune system to eliminate viral disease, announced that the Company presented new preclinical data on ABX464, ABIVAX's first-in-class drug candidate for a functional cure of patients with HIV/A
12/31/16 - Castle Creek Pharmaceuticals Announces License of Exclusive U.S. Rights for Arlevert from Hennig Arzneimittel GmbH
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Castle Creek Pharmaceuticals, LLC, a global company dedicated to delivering transformative therapies to patients with dermatologic and head/neck orphan diseases and underserved conditions, announced completion of an exclusive license agreement for all U.S. rights to Arlevert
12/31/16 - Ebola vaccine shows promise An experimental vaccine against Ebola is 100 percent effective in clinical trials
LOS ANGELES Wednesday AHF lauded the publication of clinical trial results in the journal Lancet which showed 100 percent efficacy in preventing Ebola virus infection among study participants who received an experimental vaccine in Sierra Leone and Guinea. Every year the world collectively spends almost $2 trillion on defense and only $36 billio
12/31/16 - Humacyte Commences U.S. Phase II Arterial Bypass Clinical Trial [Saudi Press Agency (Saudi Arabia)]
Humacyte, an innovator in biotechnology and regenerative medicine, announced today the initiation of a U.S. Phase II arterial bypass clinical trial of HUMACYL, its investigational human acellular vessel, to test the safety and efficacy as a lower extremity arterial bypass vessel in patients with peripheral arterial disease. The initiation of the Ph
12/31/16 - LUPIN GETS USFDA NOD FOR PITAVASTATIN TABLETS
Pharmaceutical company Lupin has received tentative approval from the United States Food and Drug Administration to market its cholesterol lowering Pitavastatin tablets in the American market. has received approval for Pitavastatin tablets in the strength of 1 milligram, 2 mg and 4 mg. Pitavastatin is a generic version of Kowa's Livalo tablets in t
12/31/16 - New Chinese Ebola vaccine safe, protective: China [Press TV (Iran)]
This file photo taken on March 10, 2015, shows a woman getting vaccinated at a health center in Conakry, Guinea, during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus. China says its first domestically-developed Ebola vaccine is a major medical breakthrough as it passed the Phase-II clinical test and gains permission for
12/31/16 - Pharmacist: New medications help with dry eyes, seizures and hallucinations
In 2016, many new and useful medications got FDA approval. My articles are syndicated worldwide, but I'm only listing English drug names so please ask your local pharmacist to translate the medication name for your country. So the FDA approved this injectable drug to help people who have been exposed from infected animals, contaimated animal produc
12/31/15 - Araim Pharmaceuticals announces a strategic partnership with Vault Bioventures to support development and commercialization of ARA 290 as well as other peptides within a novel family
Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in.
12/31/15 - Basilea provides clinical program updates
Release date- 28122015- Basilea Pharmaceutica Ltd. today provided an update on the planned clinical phase 3 development program for its antibiotic ceftobiprole in the United States and reported completion of patient recruitment and interim data from the ongoing phase 1/ 2 a study with the intravenous formulation of its oncology drug candidate BAL10
12/31/15 - Braeburn Pharmaceuticals and Camurus enroll first patient in a phase 3 efficacy trial of long-acting treatment for opioid dependence [Tripoli Post, The (Libya)]
-Princeton, New Jersey and Lund, Sweden 30 December 2015 Braeburn. Pharmaceuticals and Camurus announce that the first patient has been randomized. in the double blind Phase 3 efficacy trial of CAM2038 in opioid-dependent.
12/31/15 - Clovis Oncology Receives Notification of PDUFA Extension for Rociletinib
By a News Reporter-Staff News Editor at Politics& Government Week Clovis Oncology, Inc. announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for Clovis' New Drug Application for rociletinib by the standard extension period of three months with the new goal date of June 28, 2016. Clovis Oncology
12/31/15 - FDA awards stem cell co Pluristem orphan drug status [Globes, Tel Aviv, Israel]
Dec. 31 Israeli placenta-based cell therapy developer Pluristem Therapeutics Ltd. has been awarded orphan drug status by the US Food and Drug Administration for its PLX-PAD cells treatment for severe preeclampsia. We are encouraged by the US FDA designation that demonstrates Pluristem's commitment to the program and the potential promise it holds
12/31/15 - Global Blood Therapeutics Receives FDA Orphan Drug Designation for GBT440 in Sickle Cell Disease
Global Blood Therapeutics, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs, announced today that the U.S. Food and Drug Administration has granted orphan drug designation for GBT440 for the treatment of patients with sickle cell disease.
12/31/15 - Industry-financed clinical trials on the rise, as number of NIH-funded trials falls
By a News Reporter-Staff News Editor at Politics& Government Week Since 2006, the number of industry-sponsored clinical trials studying the benefits and harms of medical treatments has risen dramatically, while the number of clinical trials funded by the National Institutes of Health has fallen substantially, according to new Johns Hopkins Bloomb
12/31/15 - LifeSci Capital Initiates Coverage of TetraLogic Pharmaceuticals Corporation
NEW YORK, NY/ ACCESSWIRE/ December 31, 2015/ LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for cancer and infectious diseases.
12/31/15 - Market Overview on Deep Brain Stimulators - Medical Devices Pipeline Assessment, 2015, Medical Market Research, Trends and Forecast to Dominate Industry
The Report Deep Brain Stimulators- Medical Devices Pipeline Assessment, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Deep Brain Stimulators- Medical Devices Pipeline Assessme
12/31/15 - Market Overview on Proliferative Vitreoretinopathy (PVR) Global Clinical Trials Review, H2, 2015, Industry Analysis, Market Forecast to Dominate Pharma Industry
The Report Proliferative Vitreoretinopathy Global Clinical Trials Review, H2, 2015 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants.Albany, NY 12/31/2015 MarketResearchReports.Biz presents this most up-to-date research on "Proliferative Vitreoretinopathy Global Clinical...
12/31/15 - NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinsons Disease [Daily Tribune (Bahrain)]
-NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the companys continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments..
12/31/15 - PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs [Arab News (Saudi Arabia)]
-PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today a shareholder update on PharmaCytes pancreatic cancer and diabetes programs. Manuel Hidalgo, and experts at Translational Drug...
12/31/15 - PLURISTEM THERAPEUTICS INC FILES (8-K) Disclosing Other Events
On December 31, 2015, the registrant announced that the U.S. Food and Drug Administration has granted the registrant's PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia.
12/31/15 - Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval...
Researchers Submit Patent Application, "Method of Treating an Ocular Disease and Compositions Effective for Treating an Ocular Disease", for Approval. By a News Reporter-Staff News Editor at Women's Health Weekly From Washington, D.C., NewsRx journalists report that a patent application by the inventors Karla, Pradeep K.; Mangat, Harpal S., filed
12/31/15 - Rfa fibre for bipolar intraluminal application for varicose veins detail specification :us fda/european ce approved quality. inclusive of rental and... [TendersInfo (India)]
Tenders are invited for Rfa Fibre For Bipolar Intraluminal Application For Varicose Veins Detail Specification: Us Fda/ European Ce Approved Quality. Instructions/Remarks: All The Firms Participating In E-Tender Enquiry To Upload The Details Of The Offered Item In The Form Of Scanned Copy Of The Photo Of The Offered Item Showing All Relevant Detail
12/31/15 - Roche Submits Anti-Mullerian Hormone Assay for FDA Approval
By a News Reporter-Staff News Editor at Women's Health Weekly Roche announced that it has filed a direct de novo application to the U.S. Food and Drug Administration for a fully automated Anti-Mullerian assay for use on Roche's full portfolio of laboratory analyzers. Alan Wright, Chief Medical Officer, Roche Diagnostics Corporation. The assay is
12/31/15 - Teligent, Inc. Announces Fourteenth & Fifteenth ANDA Submissions Of 2015
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, today announced it has submitted its fourteenth and fifteenth abbreviated new drug applications to the U.S. Food and Drug Administration of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to thirty-three. We believe our current p
12/31/15 - U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced that the U.S. Food and Drug Administration has granted the Company s PLX-PAD cells Orphan Drug Designation in the treatment of severe preeclampsia. Attainment of Orphan Drug Designation for our cells in severe preeclampsia exemplifies o
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415